TABLE OF CONTENTS
Volume 12, Issue S1 (October 2005)
Introduction
The 3rd European conference and practical course on advanced gene vector technologies: training on pharmaceutical development of gene therapy products
M Mezzina
Gene Ther 12: S1-S4; doi:10.1038/sj.gt.3302652
Conference Papers
Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications
E Burova and E Ioffe
Gene Ther 12: S5-S17; doi:10.1038/sj.gt.3302611
Gutless adenovirus: last-generation adenovirus for gene therapy
R Alba, A Bosch and M Chillon
Gene Ther 12: S18-S27; doi:10.1038/sj.gt.3302612
Retroviral vector production in the National Gene Vector Laboratory at Indiana University
K Cornetta, L Matheson and C Ballas
Gene Ther 12: S28-S35; doi:10.1038/sj.gt.3302613
Real-time quantitative PCR for the design of lentiviral vector analytical assays
C Delenda and C Gaillard
Gene Ther 12: S36-S50; doi:10.1038/sj.gt.3302614
Current issues in adeno-associated viral vector production
O-W Merten, C Gény-Fiamma and A M Douar
Gene Ther 12: S51-S61; doi:10.1038/sj.gt.3302615
Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques
A M Duffy, A M O'Doherty, T O'Brien and P M Strappe
Gene Ther 12: S62-S72; doi:10.1038/sj.gt.3302616
Use of adenoviral vectors as veterinary vaccines
T B Ferreira, P M Alves, J G Aunins and M J T Carrondo
Gene Ther 12: S73-S83; doi:10.1038/sj.gt.3302618
Adenovirus as vehicle for anticancer genetic immunotherapy
P Gallo, S Dharmapuri, B Cipriani and P Monaci
Gene Ther 12: S84-S91; doi:10.1038/sj.gt.3302619
Biology and application of alphaviruses in gene therapy
K Lundstrom
Gene Ther 12: S92-S97; doi:10.1038/sj.gt.3302620
Development and application of replication-incompetent HSV-1-based vectors
E Berto, A Bozac and P Marconi
Gene Ther 12: S98-S102; doi:10.1038/sj.gt.3302623
Downstream processing of viral vectors and vaccines
R Morenweiser
Gene Ther 12: S103-S110; doi:10.1038/sj.gt.3302624
Cellular factors influencing Semliki Forest Virus vector biology
E Piver, C Collin, A Diatta, P Vaudin and J-C Pagès
Gene Ther 12: S111-S117; doi:10.1038/sj.gt.3302625
Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects
E P Papapetrou, N C Zoumbos and A Athanassiadou
Gene Ther 12: S118-S130; doi:10.1038/sj.gt.3302626
Validation overview of bio-analytical methods
M Tuomela, I Stanescu and K Krohn
Gene Ther 12: S131-S138; doi:10.1038/sj.gt.3302627
Intelligent polymers as nonviral vectors
S Dinçer, M Türk and E Pi
kin
Gene Ther 12: S139-S145; doi:10.1038/sj.gt.3302628
Gene therapy bio-safety: scientific and regulatory issues
P Gonin, C J Buchholz, M Pallardy and M Mezzina
Gene Ther 12: S146-S152; doi:10.1038/sj.gt.3302629
HSV-1-derived recombinant and amplicon vectors for preventive or therapeutic gene transfer: an overview
Alberto L Epstein
Gene Ther 12: S153-S153; doi:10.1038/sj.gt.3302630
HSV-1-based amplicon vectors: design and applications
Alberto L Epstein
Gene Ther 12: S154-S158; doi:10.1038/sj.gt.3302617
Angiogenic and antiangiogenic gene therapy
M Malecki, P Kolsut and R Proczka
Gene Ther 12: S159-S169; doi:10.1038/sj.gt.3302621
